Eagle Pharmaceuticals Inc (EGRX) — Capital Reinvestment Ratio
Latest as of December 2022:
0.00x
Eagle Pharmaceuticals Inc (EGRX) has a Capital Reinvestment Ratio of 0.00x as of December 2022, meaning it reinvests 0% of its operating cash flow ($37.56 Million) in capital expenditures ($10.00K). See Eagle Pharmaceuticals Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$37.56 Million
USD
Capital Expenditures
$10.00K
USD
Data as of
Dec 2022
Most recent filing
Eagle Pharmaceuticals Inc Capital Reinvestment Ratio (2016–2022)
This chart tracks Eagle Pharmaceuticals Inc's Capital Reinvestment Ratio across 7 annual periods.
Annual Capital Reinvestment Ratio for Eagle Pharmaceuticals Inc (2016–2022)
Year-by-year Capital Reinvestment Ratio for Eagle Pharmaceuticals Inc from 2016 to 2022. For live market cap and broader valuation context, see Eagle Pharmaceuticals Inc (EGRX) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.01x | $30.80 Million | $178.00K | ▼ -49.5% |
| 2021 | 0.01x | $28.22 Million | $323.00K | ▼ -24.2% |
| 2020 | 0.02x | $49.50 Million | $747.00K | ▲ +8.7% |
| 2019 | 0.01x | $55.99 Million | $777.00K | ▲ +446.6% |
| 2018 | 0.00x | $52.38 Million | $133.00K | ▼ -97.1% |
| 2017 | 0.09x | $58.92 Million | $5.19 Million | ▼ -77.4% |
| 2016 | 0.39x | $53.21 Million | $20.69 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow